Biotechnology of Human Plasma-Derived Medicines in Scope of Collaboration Perspectives within The Central European Initiative
|
|
- Ada Griffin
- 6 years ago
- Views:
Transcription
1 Biotechnology of Human Plasma-Derived Medicines in Scope of Collaboration Perspectives within The Central European Initiative Dr Vadim Sentchouk PHARMLAND LLC Deputy General Director PLASMAPHARM LLC General Manager
2 PHARMLAND COMPANY: brief description 1998 Belarus-Dutch joint venture Pharmland LLC was born. Investments from Netherlands ( ) - near 42 million US $ 308 employees Revenue 2017 (estimated) near 30 million US $ R&D Center GMP Certificates, ISO 9001 Manufacturing facilities sq.m. for: Tablets, Capsules, Sashes, Infusion solutions, Injections, Prefilled Syringes, Lyophilized Powders, Syrups, Suspensions, Medical Devices, Plasma-derived Products 2
3 HUMAN BLOOD PLASMA Human Blood Plasma is the liquid component of whole blood, and makes up approximately 55% of the total blood volume. It is composed primarily of water with small amounts of minerals, salts, ions, nutrients, and PROTEINS in solution. In whole blood, red blood cells, leukocytes, and platelets are suspended within the plasma. FRESH FROZEN PLASMA Plasma intended for the recovery of proteins that are labile in plasma is immediately frozen by cooling rapidly in conditions validated to ensure that a temperature of - 25 C or below is attained at the core of each plasma unit within 1 h of placing in the freezing apparatus. 3
4 FRACTIONATION OF HUMAN PLASMA The technology of plasma fractionation was first described in USA by Edwin J. Cohn in Modern technologies of plasma fractionation include technologies for the separation of biomolecules intended for the manufacture of plasma-derived products. Plasma Fractionation Plant chromatography, ultrafiltration, ultracentrifugation, nano-filtration, virus inactivation. 4
5 HUMAN PLASMA FOR FRACTIONATION (Monograph of European Pharmacopoeia and Belarus Pharmacopoeia) Liquid part of human blood; Intended for the manufacture of plasma-derived products. Collected from carefully selected, healthy donor free from detectable agents of transmissible infections. 5
6 PLASMA COLLECTION PLASMA CENTER In more than 600 specialized donation centers located in the U.S., Europe, and Canada, individuals may donate plasma through a process called plasmapheresis. Plasmapheresis is a sterile, self-contained, automated process where plasma is separated from red blood cells and other cellular components of blood which are then returned to the donor. Source plasma collection in the U.S. is regulated by the U.S. Food and Drug Administration (FDA) and, in Europe by the European Medicines Agency (EMA) and national regulatory authorities. 6
7 LABORATORY TESTS ARE CARRIED OUT FOR EACH DONATION TO DETECT THE FOLLOWING VIRAL MARKERS: antibodies against human immunodeficiency virus (anti-hiv-1 and anti-hiv-2) + HIV virus RNA hepatitis B surface antigen (HBsAg) + hepatitis B virus DNA antibodies against hepatitis C virus (anti-hcv) + hepatitis C virus RNA 7
8 THE PLASMA FRACTIONATION INDUSTRY is a sector of the Biopharmaceutical industry in which the plasma component of human blood is processed to produce therapeutic products. Europe and North America, with 77% of the plants, accounted for a combined 88% of global fractionation capacity. The Global Plasma Fractionation Market is estimated to grow to reach USD billion by 2021 from USD billion in The Europe Plasma Fractionation Market is estimated to grow to reach 7.04 USD billion by 2021 from 5.24 USD billion in Europe holds the second position of global market. Growth in this market is mainly attributed to growing aging population, rising incidences of bleeding and immune disorders, and growing use of immunoglobulin and alpha-1-antitrypsin. 8
9 In 2016 the top 5 players possessed 78% of total global fractionation capacity: Baxalta Inc. / Shire, USA / Ireland CSL Ltd., Australia Grifols S.A., Spain Octapharma AG, Switzerland Creat Group, China (RAAS Group, China / Bio Product Laboratory Ltd., UK / Biotest AG, Germany) Kedrion S.P.A, Italy LFB S.A., France Sanquin, Netherlands 9
10 PLASMA PROTEINS FOR CLINICAL USE Plasma Protein Albumin Immunoglobulins: Intravenous, Subcutaneous, Specific Coagulation factor VIII Von Willebrand Factor Coagulation factor IX Coagulation Factor X Coagulation factor XIII Prothrombin Complex Concentrate C1 inhibitor Antithrombin III Fibrinogen Alpha-I-Antitrypsin Indications for Clinical Use restoring of blood volume in trauma, burns and surgery patients, hypoalbuminemia passive prophylaxis, primary immunodeficiency disease, secondary immune deficiency diseases, Kawasaki's disease, chronic lymphocytic leukemia or HIV infection during childhood to prevent bacterial infections, bone marrow transplantation to prevent graft versus host disease and bacterial infections, immune thrombocytopenic purpura, Guillain Barré syndrome, polyneuropathies and other neurological disorders hemophilia A, genetic deficiency genetic deficiency hemophilia B, genetic deficiency genetic deficiency genetic deficiency hemophilia B, anticoagulant overdose hereditary angioedema congenital deficiency, disseminated intravascular coagulation congenital deficiency, massive haemorrhage hereditary deficiencies, emphysema and COPD cirrhosis 10
11 Country Population Potential Plasma for Fractionation Collection National state owned fractionator Private owned fractionator Plasma Fractionation Capacilty Open markets to products fulfilling relevant regulatory requirements Self-sufficiency In Human Plasma and Products Austria L No Octapharma, Austria L Yes Albania L No No 0 Yes No Belarus L «RNPC Transfusiology and medbiotechnology» Pharmland JV LLC L L Yes Bulgaria L No No 0 Yes No Bosnia and Herzegovina L No No 0 Yes No Hungary L No Kedrion, Italy L Italy L No Kedrion, Italy L Macedonia L No No 0 Yes No Моldova L No No 0 Yes No Poland L No No 0 Yes No Romania L No No 0 Yes No Serbia L No No 0 Yes No Slovakia L No No 0 Yes No Slovenia L No No 0 Yes No Ukraine L Blood Centers Biofarma L Yes Croatia L No No 0 Yes No Montenegro L No No 0 Yes No Czech Republic L No No 0 Yes No Total (CEI) L Total (USA) L (2016) L (2007) 11
12 Country Population Potential Plasma for Fractionation Collection Austria L Albania L Belarus L Bulgaria L Bosnia and Herzegovina L Hungary L Italy L Macedonia L Моldova L Poland L Romania L Serbia L Slovakia L Slovenia L Ukraine L Croatia L Montenegro L Czech Republic L Total (CEI) L Total (USA) L (2016) L (2007) 12
13 13
14 PHARMLAND HUMAN PLASMA PLANT: brief history The new Plasma plant was constructed according to the Investment Agreement between Pharmland JV LLC and Government / Ministry of Health of the Republic of Belarus from 3 August, 2013, and in force till Investments 23 million US$. The construction of Plasma Plant was finished in During analytical equipment, technological skids and systems were installed, Plasma Plant validations finished. The first fractionation trials with plasma batches, albumin and immunoglobulin purification started from October Marketing Authorization, GMP certification, regular fractionation of plasma, plasma-derived products manufacturing and sales from December 2017 March
15 PHARMLAND PHARMACEUTICAL PLASMA-DERIVED PRODUCTS: ALBUPHARM - Albumin solutions (Eur./Belarus Pharm.): 5% solution 20% solution 25% solution IMMUNOPHARM - Intravenous Immunoglobulin (IVIG) solutions (Eur./Belarus Pharm.): 5% solution 10% solution 16,5% solution PHARMACLOT - Coagulation Factor VIII (Eur./BelarusPharm.): Lyophilized powder 500 I.U., 1000 I.U. per vial. PHARMAFIX - Coagulation Factor IX (Eur./Belarus Pharm.): Lyophilized powder 500 I.U., 1000 I.U. per vial. 15
16 16
17 PHARMLAND PLASMA PLANT CAPACITY: L of plasma per year for fractionation and manufacturing of finished products for Belarus and other markets L of plasma for Belarus market 2017 (100%): Albumin near 1250 kg (from L of plasma), IVIG near 120 kg (from L of plasma), CF VIII near 35 mln IU (from L of plasma), CF IX near 5 mln IU (from L of plasma), Up to L of plasma per year for fractionation and manufacturing of intermediates (cryopaste, prothrombin complex, fraction II+III (or II), fraction V) and finished products for other markets 17
18 PLASMA SOURCES FOR PHARMLAND PLASMA PLANT : L now available, collected by the government plasma centers; Ministry of Health of the Republic of Belarus shall be obliged to supply plasma for fractionation according to the Investment Agreement with Pharmland; L will be available in , collected by the government plasma centers according to the Investment Agreement with Pharmland; L will be available within , collected by Pharmland owned plasma centers; Pharmland started its own investment project at the end of 2016; up to L Pharmland is now in negotiations to buy additional plasma from Georgia, Latvia, Poland, and.. 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
34 34
35 35
36 36
37 37
38 38
39 39
40 Matteo Renzi Prime Minister, Italy Maria Linna Marcucci Co-owner of Kedrion Biopharma s.p.a, Italy Vadim Sentchouk Pharmland LLC 40 Deputy General Director
41 Perspectives of Collaboration in Biotechnology of Human Plasma- Derived Medicines on the strategic objectives of the Central European Initiative Pharmland Plasma Fractionation Plant with L Plasma Fractionation capacity: Albumin products for 84 million people Immunoglobulin products for 45 million people Coagulation Factors products for 45 million people Support CEI Member States on their path towards regional and European integration and cooperation in: Plasma Collection, Plasma Fractionation, Manufacturing of Plasma-Derived Medicinal Products, Investigation of NEW Plasma-Derived Medicinal Products, Support CEI Member States on their path to reach self-sufficiency in Human Plasma and Plasma-derived Products 41
42 We be of one blood, ye and I from "The Jungle Book" by Rudyard Kipling (1894) 42
IG Production and Safety
IG Production and Safety Platelet Disorder Support Association July 20, 2013 Mary Gustafson, Vice President, PPTA Global Regulatory Policy Presentation Outline Introduction - PPTA Plasma Collection Final
More informationCONTRACT FRACTIONATION
FACTS AND FIGURES APRIL 2008 NO 5 CONTRACT FRACTIONATION Third Edition Prepared by the World Federation of Hemophilia Published by the World Federation of Hemophilia (WFH), 1998; revised 2004, 2008. World
More informationASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS
ASSESSING THE EFFICACY AND SAFETY OF NORMAL INTRAVENOUS IMMUNOGLOBULIN PRODUCTS FOR MARKETING AUTHORISATIONS Guideline Title Assessing the Efficacy and Safety of Normal Intravenous Immunoglobulin Products
More informationPlasma fractionation: Technical and organisational points to consider
IPFA workshop Yogyakarta, Indonesia March 2 nd -3 rd, 2017 醫學工程學院 College of Biomedical Engineering Plasma fractionation: Technical and organisational points to consider Thierry Burnouf, Prof., PhD College
More informationPlasma fractionation in China: progress and challenges
Perspective Page 1 of 6 Plasma fractionation in China: progress and challenges Ya Wang, Zongkui Wang, Bin Liu, Xiaoqian Huang, Wenhui Li, Changqing Li Institute of Blood Transfusion, Chinese Academy of
More informationFrom the ancient Greeks and Arabs to
AUTHORS Grifols. Corporate Communications and Medical & Technical Departments. Therapeutic plasma proteins: their incredible potential as a source of health From the ancient Greeks and Arabs to Leonardo
More informationRecent market status and trends of fractionated plasma products
Perspective Page 1 of 6 Recent market status and trends of fractionated plasma products Matthew Hotchko, Patrick Robert Marketing Research Bureau, Inc., Orange, Connecticut, USA Correspondence to: Matthew
More informationHuman Protein Process Sciences, Lille, France 2. Shabrawishi Hospital Blood Bank, Cairo, Egypt 3. University of Saskatoon, Canada
1 Human Protein Process Sciences, Lille, France 2 Shabrawishi Hospital Blood Bank, Cairo, Egypt 3 University of Saskatoon, Canada Why such a concept? Non-virally inactivated plasma components are still
More informationPlasma Fractionation Today and in the Future Plasma Product Biotechnology Meeting
Plasma Fractionation Today and in the Future 2013 Plasma Product Biotechnology Meeting 1 What we do matters Dayna and her husband, Brian, are the parents of four wonderful, amazing children, Charlie, Kate,
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationCost effectiveness of Iran national plasma contract fractionation program
Cheraghali DARU Journal of Pharmaceutical Sciences 2012, 20:63 REVIEW ARTICLE Cost effectiveness of Iran national plasma contract fractionation program Abdol Majid Cheraghali Open Access Abstract Plasma
More informationLeadership in Immunology through Innovation, Global Execution, and Patient Support. Perry Sternberg, Head US Commercial
Leadership in Immunology through Innovation, Global Execution, and Patient Support Perry Sternberg, Head US Commercial Summary Shire is well positioned for further growth in Immunology Global immunology
More informationHaemophilia care in Europe: a survey of 19 countries
Haemophilia (2011), 17, 35 40 DOI: 10.1111/j.1365-2516.2010.02362.x ORIGINAL ARTICLE Clinical haemophilia Haemophilia care in Europe: a survey of 19 countries B. O MAHONY,* D. NOONE,* P. L. F. GIANGRANDE
More informationGlobal Blood Plasma Market Report
Global Blood Plasma Market Report ----------------------------------------- 2015 Executive Summary The raw material for blood plasma industry is the straw colored liquid that is a component of blood called
More informationEuropean Haemophilia Safety Surveillance System (EUHASS) Mike Makris Sheffield, UK
European Haemophilia Safety Surveillance System (EUHASS) Mike Makris Sheffield, UK Pharmacovigilance Voluntary by health professionals and patients Often not used Too busy, not aware of the scheme Believe
More informationA 70-year history of improving the quality of life for patients
Press Book 2013 Grifols is A world-leading manufacturer of plasmabased biological medicines A 70-year history of improving the quality of life for patients A mission to reach those patients who do not
More informationComments of American Plasma Users Coalition (A-PLUS) To the Food and Drug Administration December 31, 2010
Comments of American Plasma Users Coalition (A-PLUS) To the Food and Drug Administration December 31, 2010 The American Plasma Users Coalition (A-PLUS) is a coalition of national patient advocacy organizations
More informationGRECO IN THE MIDST OF ITS FOURTH EVALUATION ROUND. Christian Manquet, Vice-President of GRECO
GRECO IN THE MIDST OF ITS FOURTH EVALUATION ROUND Christian Manquet, Vice-President of GRECO GRECO s outreach today: 49 Member States: all Council of Europe member States as well as Belarus and the United
More informationInternational trade related air freight volumes move back above the precrisis level of June 2008 both in the EU area and in the Unites States;
Statistics Brief Global Trade and Transport October 2017 Air freight volumes increase since the second quarter of 2016 The latest update of global freight data collected by the International Transport
More informationRE: The Disproportionate Share Hospital Prohibition for Purchasing from Group Purchasing Organizations
September 23, 2009 Reference No.: FASC09051 Jimmy R. Mitchell, R.Ph, MPH, MS Director Office of Pharmacy Affairs Health Resources and Services Administration United States Department of Health & Human
More informationCategory Storage Shelf Life Additional Criteria
CE Update [blood banking/transfusion medicine] Blood Components for Hemostasis Jun Teruya, MD, DSc, and Glenn Ramsey, MD From the Department of Pathology, Northwestern University Medical School, Chicago.
More informationExcipient Albumin CSL Behring Human Serum Albumin
Excipient Albumin CSL Behring Human Serum Albumin For more information, contact CSL Behring USA: (610) 878-4000 1020 First Avenue King of Prussia, PA 19406-0901 Switzerland: +41 31 344 44 44 Wandorfstrasse
More informationGlobal Blood Plasma Market
Global Blood Plasma Market ------------------------------------------- 2013 Executive Summary Plasma is a composite mixture of more than 700 proteins and other substances which are vital for the smooth
More informationCSL Behring Aligning Quality Processes. Quality Systems within the wider business
CSL Behring Aligning Quality Processes Quality Systems within the wider business Presentation Overview CSL Company overview Aligning Quality Processes The context of process capability across the enterprise
More informationRE: Comparative Clinical Effectiveness Research Comments on S from the 110 th Congress
March 2, 2009 The Honorable Max Baucus United States Senate Washington, DC 20510 The Honorable Kent Conrad United States Senate Washington, DC 20510 RE: Comparative Clinical Effectiveness Research Comments
More informationUniversity of Groningen. Haemophilia care in Europe O'Mahony, B.; Noone, D.; Giangrande, P.L.F.; Prihodova, L. Published in: Haemophilia
University of Groningen Haemophilia care in Europe O'Mahony, B.; one, D.; Giangrande, P.L.F.; Prihodova, L. Published in: Haemophilia IMPORTANT NOTE: You are advised to consult the publisher's version
More informationBlood Component Preparation and Therapeutic Utilization
Blood Component Preparation and Therapeutic Utilization Prof. A. Pourazar Immunohematologist and Transfusion medicine School of Medicine, Isfahan University Of Medical Science IRAN Red Blood cells, Platelets
More informationFRAMEWORK CONVENTION ON CLIMATE CHANGE - Secretariat CONVENTION - CADRE SUR LES CHANGEMENTS CLIMATIQUES - Secrétariat KEY GHG DATA
UNITED NATIONS NATIONS UNIES FRAMEWORK CONVENTION ON CLIMATE CHANGE - Secretariat CONVENTION - CADRE SUR LES CHANGEMENTS CLIMATIQUES - Secrétariat KEY GHG DATA Greenhouse Gas Emissions Data for 1990 2003
More informationFactor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs
Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs Call from OR! Scenario -1 Patients is bleeding out! Don t ask why, what rate what s been done! We need blood now! What kind of
More informationMarketing Authorisation Holder Invented name Strength Pharmaceutical Form Route of administration
Annex I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State EU/EEA Marketing Authorisation
More informationDECEMBER World Federation of Hemophilia Report on the ANNUAL GLOBAL SURVEY 2008
DECEMBER 2009 World Federation of Hemophilia Report on the ANNUAL GLOBAL SURVEY 2008 Report on the Annual Global Survey 2008 is published by the World Federation of Hemophilia. All data are provisional.
More informationThe World Health Assembly Resolution on availability, safety and quality of blood products (WHA 63.12) Adopted May 2010
The World Health Assembly Resolution on availability, safety and quality of blood products (WHA 63.12) Adopted May 2010 Dr Ana Padilla Blood Products & related Biologicals Essential Medicines and Pharmaceutical
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
23 July 2015 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular
More informationFractionation Services and Recombinant Plasma Protein Products: Product Supply and Transitioning
Frequently sked uestions and Recombinant Plasma Supply and Transitioning Summary of product changes Red (underlined): not continuing Blue (bold): new Today s Product Mix Future Product Mix Product Size
More informationCellular Therapy Products & NDC vs. ISBT128 Coding/Labeling
Cellular Therapy Products & NDC vs. ISBT128 Coding/Labeling William E. Janssen, Ph.D. Director, Cell Therapies Facility Moffitt Cancer Center Tampa, Florida What is ISBT 128? Information standard for blood,
More informationNetwork of Aquaculture Centers in Central and Eastern Europe NACEE
Network of Aquaculture Centers in Central and Eastern Europe NACEE Zsigmond Jeney; Péter Lengyel; László Váradi Research Institute for Fisheries, Aquaculture and Irrigation (HAKI) Szarvas, Hungary Objectives
More informationDivision of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
Reference No.: FDAA10017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 VIA WEB SUBJECT: Approval Pathway for Biosimilar and Interchangeable
More informationIntroducing the work of FAO in the Region
Regional Office for Europe and Central Asia Introducing the work of FAO in the Region Norbert Winkler-Ráthonyi Forestry Officer, Regional Office for Europe and Central Asia (REU) Peter Pechacek Forestry
More informationAddressing Critical Healthcare Challenges Worldwide. Baxter International Inc.
Addressing Critical Healthcare Challenges Worldwide Baxter International Inc. About Our Cover Baxter products are used in more than 100 countries to save and sustain the lives of people with hemophilia,
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous
More informationAntihemophilic Products
Antihemophilic Products Factor VIII Only Advate Alphanate Eloctate Helixate FS Hemofil M Humate - P Koate - DVI Kogenate FS with Vial Adapter Kogenate FS with Bioset Monoclate - P NovoEight Recombinate
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 6 February 2009 CPMP/BPWG/388/95 rev. 2 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON
More informationFactor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate
Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary
More informationVirus Safety in Plasma- Derived Therapeutics: A Merck Perspective. IPFA Yogyakarta, March Louis Wong
Virus Safety in Plasma- Derived Therapeutics: A Merck Perspective IPFA Yogyakarta, March 2017 Louis Wong Associate director, Plasma Initiative, Asia-Pacific Content Regulatory Expectations for Plasma-Derived
More informationCrop production - Coarse grains
PART 1 Crop production - Coarse grains Coarse grains are cereal grains other than wheat and rice that include maize (corn in the United States), barley, sorghum, rye, and oats. The global demand for these
More informationCambridge International Examinations Cambridge International Advanced Subsidiary and Advanced Level
Cambridge International Examinations Cambridge International Advanced Subsidiary and Advanced Level *2029778719-I* GEOGRAPHY 9696/32 Paper 3 Advanced Human Options October/November 2015 INSERT 1 hour 30
More informationCreating Miracles in Life
Creating Miracles in Life November 2017 China Biologic Products Holdings, Inc. (NASDAQ: CBPO) Safe Harbor Statement 01 This presentation contains forward-looking statements, including statements about
More informationTHE EUROPEAN BLOOD BANKING MARKET: France, Germany, Italy, Spain, UK Emerging Opportunities and Business Expansion Strategies.
I. Introduction THE EUROPEAN BLOOD BANKING MARKET: France, Germany, Italy, Spain, UK Emerging Opportunities and Business Expansion Strategies Table of Contents II. Worldwide Technology and Market Overview
More informationCOMPLETE PRICELIST FOR POSTAL SERVICES IN INTERNATIONAL POSTAL TRAFFIC
COMPLETE PRICELIST FOR POSTAL SERVICES IN INTERNATIONAL POSTAL TRAFFIC LETTERPOST SERVICES Letter Weight (g) Regular Letter Registered Letter up to 20 70.00 220.00 from 21 to 100 170.00 320.00 from 101
More informationFACT SHEET. A CRA Perspective: The Difference between Medical Device Studies and Pharmaceutical Studies.
FACT SHEET A CRA Perspective: The Difference between Medical Device Studies and Pharmaceutical Studies Experts Providing Experts TalentSource Life Sciences is the dedicated flexible resourcing business
More informationDECISION No SCALES OF CONTRIBUTIONS FOR
Organization for Security and Co-operation in Europe Permanent Council Original: ENGLISH 1083rd Plenary Meeting PC Journal No. 1083, Agenda item 3 DECISION No. 1196 SCALES OF CONTRIBUTIONS FOR 2016 2017
More informationTechnical guide for the ELABORATION AND USE OF MONOGRAPHS ON HUMAN PLASMA- DERIVED PRODUCTS
Technical guide for the ELABORATION AND USE OF MONOGRAPHS ON HUMAN PLASMA- DERIVED PRODUCTS European Pharmacopoeia EDQM 2015 Technical guide for the ELABORATION AND USE OF MONOGRAPHS AND GENERAL CHAPTERS
More informationSTRATEGIES FOR NANOFILTRATION OF THERAPEUTIC PLASMA PROTEINS
STRATEGIES FOR NANOFILTRATION OF THERAPEUTIC PLASMA PROTEINS Oral Presentation: Pere Ristol Faro M, Canal JM, Marzo N, Caballero S, Belda F, Gajardo R, Grancha S, Ristol P R&D Area, Instituto Grifols S.A.
More informationDEAR SHAREHOLDERS, I would like to end by thanking everyone, once again, for the trust they have placed in our management of the company.
ANNUAL 2015 REPORT DEAR SHAREHOLDERS, Before reviewing our results for 2015, I would like to take a moment to recall that this year also saw us celebrate our 75th anniversary: three quarters of a century
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 22 October 2012
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA PHARM 608 PHARMACEUTICAL COMMITTEE 22 October 2012 Subject: Hospital exemption
More informationGrifols net profit up by +6.2% to million euros and sales grow by +13.8% in the first quarter of 2015
Grifols net profit up by +6.2% to 128.5 million euros and sales grow by +13.8% in the first quarter of 2015 Income grows by +13.8% (+1.1% constant currency (cc) 1 ) to Euros 908.4 million, driven by sales
More informationAntihemophilic Products
Antihemophilic Products Factor IX Only AlphaNine SD Alprolix Kit BEBULIN VH BeneFIX RT Mononine Profilnine SD Additional Antihemophilic Products ATryn Corifact FEIBA Kcentra NovoSeven RT RiaSTAP RIXUBIS
More informationRiastap 1 g Powder for solution for injection / infusion Human fibrinogen
Package Leaflet: Information for the user Riastap 1 g Powder for solution for injection / infusion Human fibrinogen Read all of this leaflet carefully before you start using this medicine because it contains
More informationGENERAL PHARMACOPOEIA MONOGRAPH
MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION GENERAL PHARMACOPOEIA MONOGRAPH Immunobiological GPM. 1.8.1.0002.15 medicinal products First Edition The present General Pharmacopoeia Monograph applies to
More informationCURRENT CONSIDERATION FOR INTRAVENOUS IMMUNOGLOBULIN IN NIB INDIA
CURRENT CONSIDERATION FOR INTRAVENOUS IMMUNOGLOBULIN IN NIB INDIA Dr. J. P. PRASAD HEAD, BLOOD PRODUCTS LABORATORY Presentation Plan Regulation of Blood & Blood Products in India Evolution of Blood safety
More informationCAP CONTEXT INDICATORS
CAP CONTEXT INDICATORS 2014-2020 24. AGRICULTURAL TRAINING OF FARM MANAGERS 2017 update CONTEXT INDICATOR 24: AGRICULTURAL TRAINING OF FARM MANAGERS Learning by doing is still the main form of for the
More informationMIPCOM 2017 Market Snapshot: Europe. Top SVOD titles and genre trends: Demand share and YoY growth
MIPCOM 2017 Market Snapshot: Europe Top SVOD titles and genre trends: Demand share and YoY growth Top 10 European SVOD titles Discover the most in-demand Digital Originals in Europe for the year to date.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.44 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationPlasma derived medicines - the evidence for their necessity
Plasma derived medicines - the evidence for their necessity FACULTY OF MEDICINE, DENTISTRY AND HEALTH SCIENCES ALBERT FARRUGIA PHD Disclosures I provide compensated services for the manufacturers of therapies
More informationInformation Sheet. A plasma contract fractionation program. General considerations
Information Sheet Plasma Contract Fractionation Program General considerations The provision of safe and sufficient plasma derivatives to meet the needs of local populations in all countries reuires special
More informationPatients Perspective in Plasma Products (Focus on Hemophilia)
Original Article Patients Perspective in Plasma Products (Focus on Hemophilia) Mohammad Faranoush Associate Professor, Pediatric Hematologist Oncologist, Iranian Blood Transfusion Organization Tehran,
More informationPatients Perspective in Plasma Products (Focus on Hemophilia)
Original Article Patients Perspective in Plasma Products (Focus on Hemophilia) Mohammad Faranoush Associate Professor, Pediatric Hematologist Oncologist, Iranian Blood Transfusion Organization Tehran,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 27 April 2006 CPMP/BPWG/575/99 Rev. 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CLINICAL
More informationState of Europe's Forests production processs and report. Roman Michalak, UNECE/FAO Forestry and Timber Section. State of Europe s Forests 2011
FORESTRY STATISTICS WORKING GROUP EUROSTAT, Luxembourg 16-17 November 2011 State of Europe's Forests 2011 - production processs and report Roman Michalak, State of Europe s Forests 2011 Development process
More informationPrepared for the Plasma Protein Therapeutics Association By Mike Druckman, Partner Hogan & Hartson LLP. June 4, \\\DC / v7
Patients Who Depend On Plasma Protein Therapies Need Legislative Protection From Unpredictable Risks To Which An Abbreviated Product Approval Pathway Could Expose Them Prepared for the Plasma Protein Therapeutics
More informationGLOBAL TELECOMMUNICATIONS MARKETS & FORECASTS FOR THE TELESEEQ YEARBOOK FROM INFOCOM ENHANCED WITH ONLINE ACCESS
GLOBAL TELECOMMUNICATIONS MARKETS & FORECASTS FOR 2007-2011 THE FROM INFOCOM ENHANCED WITH ONLINE ACCESS GLOBAL TELECOMMUNICATIONS MARKETS & FORECASTS FOR 2007-2011 Regional trends, market values, global
More informationPlasma fractionation 2011 and beyond
The not-for-profit fractionators view Jan Over Plasma Products division PPB11, Cyprus, May 9-12, 2011 1 Outline The plasma fractionation field at present Aims of the not-for-profit and for-profit sectors
More informationAir freight volumes in tonnes of goods moved, considered as a lead indicator, have recovered above pre-crisis peak in the United States and EU-28.
Statistics Brief Global Trade and Transport February 2015 Air freight volumes indicate a potential improvement of the near-term outlook The latest update of global freight data collected by the International
More informationFindings from FAOSTAT user questionnaire surveys
Joint FAO/UNECE Working party On Forest Economics and Statistics 28 th session, Geneva, 2-4 May 2006 Agenda Item 6 Dissemination of outputs During the last decade FAO has carried out two FAO forest product
More informationBLOOD FRACTIONATION FOR IVD
BLOOD FRACTIONATION FOR IVD H2B, BLOOD FRACTIONATION FOR IVD Located in Limoges (France), H2B manufactures fractionated blood products for the life sciences and IVD industries. Thanks to over 20 years
More informationBlood Product Utilization
Who gets what & when Why not to give blood? Volume Expander For specific number (except as related to procedures) To patients with religious objections to blood transfusions Blood given only when necessary
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.49 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSurface freight volumes, measured in tonne-kilometres of goods transported, show signs of a slowing down in China and Russia.
Statistics Brief Global Trade and Transport October 2015 Air Freight Volumes Indicate Slowing Growth in the Second Quarter 2015 The latest update of global freight data collected by the International Transport
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED ANTITHROMBIN
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 17 January 2002 CPMP/BPWG/3226/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC
More informationprepared by the Secretariat
Strasbourg, 10 September 2007 Study No. 426 / 2007 CDL-EL(2007)023* Engl. only EUROPEAN COMMISSION FOR DEMOCRACY THROUGH LAW (VENICE COMMISSION) NOTE ON THE ISSUE OF DISSOLUTION OF PARLIAMENT prepared
More informationManufacturing Journal Media Kit
Manufacturing Journal Media Kit Magazine Advertising Website Advertising Statistics www.manufacturing-journal.net Magazine Advertising Advertising guidelines: Follow the application s instructions : create
More informationPrior Authorization Criteria Hemophilia/Blood Factor Products
Prior Authorization Criteria Hemophilia/Blood Factor Products All requests for Hemophilia/Blood Factor Products require a prior authorization and will be screened for medical necessity and appropriateness
More informationSiemens Partner Program
Siemens Partner Program Factory Automation Partner Strategy for Factory Automation End Customer Focus on core competencies Demand on efficient solutions Certified Partner Added value in solutions and services
More informationGUIDELINES FOR IDENTIFICATION AND INDICATION OF BLOOD COMPONENTS AND BLOOD PRODUCTS.
GUIDELINES FOR IDENTIFICATION AND INDICATION OF BLOOD COMPONENTS AND BLOOD PRODUCTS. Hur sluta röka cold turkey 1. Policy Statement The Regional Health Authorities should develop policies that: 1.1 Provide
More informationPROVINCIAL BLOOD COORDINATING PROGRAM DEFINITIONS NLBCP-063
Government of Newfoundland and Labrador Department of Health and Community Services Provincial Blood Coordinating Program PROVINCIAL BLOOD COORDINATING PROGRAM DEFINITIONS Office of Administrative Responsibility
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED AND RECOMBINANT COAGULATION FACTOR IX PRODUCTS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 29 June 2000 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED
More informationSession 13: Prequalification Within the Context of Global Fund Procurements
Session 13: Prequalification Within the Context of Global Fund Procurements Established in 2002 Global Fund Attracts and disburses additional resources to prevent and treat AIDS, tuberculosis (TB), and
More informationHome truths... the clinical use of components in the UK. Jonathan Wallis. Platelets, FFP, Cryoprecipitate
Home truths... the clinical use of components in the UK Platelets, FFP, Cryoprecipitate Jonathan Wallis Mar-01 Mar-02 Mar-03 Mar-04 Mar-05 Mar-06 Mar-07 Mar-08 Mar-09 Mar-10 Mar-11 Mar-12 E&N.Wales Platelet
More informationExpert in biological products of human origin BLOOD PRODUCTS STABLE PRODUCTS STEM CELLS HUMAN TISSUES MOTHER S MILK
BLOOD PRODUCTS STABLE PRODUCTS STEM CELLS HUMAN TISSUES MOTHER S MILK Rosalie makes her first apheresis plasma donation. Expert in biological products of human origin 2016 2017 ACTIVITY REPORT MISSION
More informationPublic Assessment Report Scientific discussion. Octanate LV (human coagulation factor VIII) SE/H/1070/03-04/DC
Public Assessment Report Scientific discussion Octanate LV (human coagulation factor VIII) SE/H/1070/03-04/DC This module reflects the scientific discussion for the approval of Octanate LV. The procedure
More informationResolution CM/Res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use
Resolution CM/Res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use (Adopted by the Committee of Ministers on 1 June 2016 at the 1258th meeting
More informationEurope s Number One Medical Diagnostics Provider
Europe s Number One Medical Diagnostics Provider English www.synlab.com A network of more than 1.000 medical experts Present in more than 30 countries on 4 continents Areas of expertise: human, veterinary,
More informationForest Stewardship Council
Global FSC certified area*: by region Africa CAMEROON CONGO, THE REPUBLIC OF GABON GHANA MOZAMBIQUE NAMIBIA SOUTH AFRICA SWAZILAND TANZANIA, UNITED UGANDA Asia CAMBODIA CHINA INDIA INDONESIA JAPAN KOREA,
More informationTECHNICAL PROFILES CATALOGUE
TECHNICAL PROFILES CATALOGUE 2016 1 ULTIMATE PROFILE SOLUTIONS Table of Contents: I. lighting profiles................................8 AP 208................................................... 8 AP 404...................................................
More informationGS1 standards for unique identification of medicinal products
GS1 standards for unique identification of medicinal products Lisbon, Portugal 3 July 2013 Silverio Paixão, Chief Innovation & Standards Officier, GS1 Portugal Who is GS1? GS1 a neutral, not-for-profit,
More informationINTERNATIONAL TRADE REPORT ON ADRIATIC AND IONIAN AREA. STATISTICS DATA Update 2014
INTERNATIONAL TRADE REPORT ON ADRIATIC AND IONIAN AREA STATISTICS DATA Update 2014 Ancona, May 2015 The aim of this work is to provide a contribution to identify the economic and commercial dimension of
More informationCFI SUBMISSION FORM I. CS4 AFUAS: Advanced Flexible Use of Airspace Support Service (AFUAS)
14-110062-I CS4 AFUAS: Advanced Flexible Use of Airspace Support Service (AFUAS) This CFI Submission Form has been produced to enable to evaluate the compliance with the set requirements of the applicants
More informationGuideline on core SmPC for human fibrinogen products
23 July 2015 EMA/CHMP/BPWP/691754/2013 Rev 1 Committee for Medicinal Products for Human Use (CHMP) Draft Agreed by Blood Products Working Party 27 November 2013 Adoption by CHMP for release for consultation
More informationForest Stewardship Council
Global FSC Certified Businesses: by country PUERTO RICO 4 FINLAND 83 BAHRAIN GUATEMALA 29 MACEDONIA 3 VIETNAM 004 CONGO, THE REPUBLIC OF 5 NEW ZEALAND 287 KOREA, REPUBLIC OF 243 UGANDA 3 MONACO 4 EGYPT
More informationIntelligent Transport Systems (ITS)
UNITED NATIONS ECONOMIC COMMISSION FOR EUROPE (UNECE) Workshop on ITS in intermodal transport 15-16 May 2013, Brussels Intelligent Transport Systems (ITS) Opportunites and challenges for intermodal transport
More information